7.9% Above Target

Wall Street's consensus price target for CARE is $28.5, -7.9% from its current price of $30.96. The below-market target from 5 analysts suggests limited near-term appreciation.

CARE has a consensus rating of "Hold" based on 5 Wall Street analysts. The rating breakdown is mixed, with 4 Hold ratings making up the largest segment. The consensus 12-month price target of $28.5 implies -7.9% downside from current levels.

With a forward P/E of 5.6703x, CARE trades at a relatively low valuation. The consensus target of $28.5 implies -7.9% move, suggesting the market may be pricing in risks.

The most bullish Wall Street analyst has a price target of $30 for CARE, while the most conservative target is $27. The consensus of $28.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $53 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

CARE is moderately covered, with 5 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month CARE stock forecast based on 5 Wall Street analysts shows a consensus price target of $28.5, with estimates ranging from $27 (bear case) to $30 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $40, with bear/bull scenarios of $25/$53.

Our quantitative valuation model calculates CARE's fair value at $40 (base case), with a bear case of $25 and bull case of $53. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.

CARE trades at a forward P/E ratio of 5.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 22.1x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

Analysts are cautious on CARE, with 0 Sell ratings and a price target of $28.5 (-7.9% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

CARE analyst price targets range from $27 to $30, a 11% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $28.5 consensus represents the middle ground. Our model's $25-$53 range provides an independent fundamental perspective.